Latest updates for Bayry

Fresh curated links around BAYRY are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Recent items include:

  • Bayer: Debt Remains A Problem, Value Remains Compelling
  • TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
  • Analyst Report: Roche Holding AG

Post angles to try

Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

seekingalpha.com /1 month ago

Bayer: Debt Remains A Problem, Value Remains Compelling

Read source
seekingalpha.com /2 weeks ago

TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors

Read source
finance.yahoo.com /1 month ago

Analyst Report: Roche Holding AG

Read source
seekingalpha.com /1 month ago

Going Deeper On Disc Medicine

Read source
seekingalpha.com /4 days ago

Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum

Read source
seekingalpha.com /1 month ago

Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions

Read source
finance.yahoo.com /1 week ago

Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?

Read source
seekingalpha.com /1 week ago

BioXcel files for Chapter 11, will sell assets to Teva

Read source
finance.yahoo.com /4 weeks ago

Analyst Report: Merck & Co Inc

Read source
pharmexec.com /3 weeks ago

<![CDATA[M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration wit...

Read source
finance.yahoo.com /1 month ago

Market Update: NLY, BRO, SANM, SLB, RHHBY, BKR

Read source
seekingalpha.com /2 weeks ago

Royalty Pharma: The Quiet Compounder The Market Is Still Mispricing

Read source
seekingalpha.com /1 month ago

ImmunityBio: Intriguing Progress, If Not (Yet) Commercially - Still A Hold

Read source
investing.com /3 weeks ago

BioMarin to acquire Alesta Therapeutics for up to $490 million

Read source
seekingalpha.com /1 week ago

Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment

Read source
seekingalpha.com /3 hours ago

Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1 '27

Read source
seekingalpha.com /1 month ago

ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy

Read source
seekingalpha.com /4 days ago

XBI: Big Pharma Can Keep The 76% Rally Going

Read source
pharmexec.com /1 week ago

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

Read source
fool.com /2 weeks ago

Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing...

The company has increased its dividend for 30 consecutive years.

Read source
pharmexec.com /1 week ago

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

Read source
pharmexec.com /1 week ago

<![CDATA[Simcere Zaiming Licenses Sim0660 to Roche for $1.53 billion]]>

Read source
seekingalpha.com /1 month ago

BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript

Read source
seekingalpha.com /1 month ago

BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Sources covering Bayry

seekingalpha.com

Recent coverage from public sources
Public source

finance.yahoo.com

Recent coverage from public sources
Public source

seekingalpha.com

Recent coverage from public sources
Public source

seekingalpha.com

Recent coverage from public sources
Public source

fool.com

Recent coverage from public sources
Public source

investing.com

Recent coverage from public sources
Public source